Oncopeptides AB (publ) (STO:ONCO)

Oncopeptides AB Revenue

Oncopeptides AB had revenue of 31.10M SEK in the quarter ending June 30, 2026, with 62.12% growth. This brings the company's total for the last twelve months to 95.15M, up 87.05% year-over-year. In the year 2025, Oncopeptides AB had annual revenue of 71.12M with 124.72% growth. That makes Oncopeptides AB the 37,526th largest company in the world by revenue and 503rd in Sweden.

• Revenue (ttm): 95.15M
• Revenue Growth: +87.05%
• P/S Ratio: 6.95
• Revenue / Employee: 1.38M
• Employees: 69
• Market Cap: 658.55M

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Germany 30.82M 43.3%
• Italy 17.06M 24.0%
• Spain 12.75M 17.9%
• Greece 8.56M 12.0%
• Austria 1.57M 2.2%
• Other Countries 352.00K 0.5%

Fiscal year ended Dec 31, 2025 See the full Oncopeptides AB breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	71.12M	39.47M	124.72%
Dec 31, 2024	31.65M	-3.57M	-10.14%
Dec 31, 2023	35.22M	26.87M	321.54%
Dec 31, 2022	8.36M	-109.94M	-92.94%
Dec 31, 2021	118.30M	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error